Latest Research And Development News

HighCom Limited reports a sharp 90% reduction in net loss for FY25, turning EBITDA positive and advancing new product development with XTclave technology. Leadership changes and strategic focus set the stage for growth despite cautious US market conditions.

Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

DorsaVi Limited reported a 13.9% revenue decline and a 21.7% rise in net loss for FY25, while securing over $3 million in capital to fuel new technology ventures.

Immuron Limited reported a strong 48.6% revenue increase driven by Travelan sales in Australia and North America, yet still recorded a $5.25 million net loss for FY25. The company’s cash reserves fell sharply, prompting a post-year capital raise.

Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Next Science reports a 42% improvement in adjusted EBITDA loss for 1H FY25 despite a 7% dip in product sales, while shareholders approve a major asset sale to OSARTIS GmbH.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.